--Analyst Actions: BofA Securities Initiates BioXcel Therapeutics Coverage at Buy, Price Target $45
11:11AM ET 4/01/2020 MT NewswiresPrice: 21.63, Change: -0.72, Percent Change: -3.22 ...
Quotes Snapshot > BTAI
BioXcel Therapeutics Inc BTAI:NASDAQ
Last Price$17.62NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/03/20
Today's Change-1.13(6.03%)
Bid (Size)$17.70 (2)
Ask (Size)$18.50 (2)
Day Low / High$16.00 - 19.42
Volume416.3 K
Read more news Recent News
BioXcel Therapeutics Doses More Than One-Third of Patients in Anti-Agitation Treatment Study
8:26AM ET 3/19/2020 MT NewswiresBioXcel Therapeutics (BTAI) said pre-market Thursday that more than one-third of the patients in the phase 3 trials of its investigative anti-agitation...
--Analyst Actions: HC Wainwright Raises Price Target for Buy-Rated BioXcel Therapeutics to $95 From $30, Shares Rally 11%
2:18PM ET 2/26/2020 MT NewswiresPrice: 33.11, Change: +3.38, Percent Change: +11.37 ...
--Analyst Actions: Canaccord Genuity Lifts Price Target on BioXcel Therapeutics to $68 From $27, Reiterates Buy Rating
10:07AM ET 2/21/2020 MT NewswiresPrice: 35.18, Change: +0.98, Percent Change: +2.87 ...
View all Commentary and Analysis
BioXcel Therapeutics (BTAI) Presents At Barclays Global Healthcare Conference - Slideshow
5:52PM ET 3/10/2020 Seeking AlphaBioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2019 Results - Earnings Call Transcript
11:06AM ET 3/09/2020 Seeking AlphaBioXcel Therapeutics: AI-Focused Biopharmaceutical Player For 2020
2:37PM ET 1/23/2020 Seeking AlphaBioXcel Therapeutics (BTAI) Investor Presentation - Slideshow
12:31PM ET 12/09/2019 Seeking AlphaCompany Profile
Business DescriptionBioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
| Address | 555 Long Wharf Drive New Haven, Connecticut 06511 |
| Phone | +1.475.238.6837 |
| Number of Employees | 18 |
| Recent SEC Filing | 03/09/2020 8-K |
| President, CEO, Secretary & Director | Vimal D. Mehta |
| Chief Financial Officer & Vice President | Richard I. Steinhart |
| Chief Scientific Officer | Frank D. Yocca |
| Chief Medical Officer & Senior Vice President | Vincent J. O'Neill |
Company Highlights
| Price Open | $18.82 |
| Previous Close | $18.75 |
| 52 Week Range | $3.76 - 43.63 |
| Market Capitalization | $355.6 M |
| Shares Outstanding | 20.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 05/05/2020 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$2.03 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -110.97% |
Analyst Ratings as of 04/01/2020
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |